secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001437749-22-005156
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Q4 net income $4.2M vs loss; FY loss narrows to $29.1M from $60.0M
-----------------------------------------------------------------------

- Q4 product revenue $51.0M (+2% YoY); total revenue $55.4M including $1.5M license and $2.9M royalty.
- GAAP net income Q4 $4.2M ($0.10 EPS) vs loss of $15.0M ($0.38 loss) in Q4 2020.
- FY 2021 net loss $29.1M ($0.72 loss) vs $60.0M loss ($1.52 loss); non-GAAP adjusted net income $3.5M.
- Cash and securities $82.1M at Dec 31; operating cash flow $20.7M provided in FY 2021 vs $0.8M in FY 2020.
- Key 2022 catalysts: pre-NDA meeting for neratinib HER2-mutant breast cancer, Phase II data in multiple indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922005156/0001437749-22-005156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922005156/pbyi20220228_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-005156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer